1. Home
  2. SNTG vs ARTL Comparison

SNTG vs ARTL Comparison

Compare SNTG & ARTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SNTG
  • ARTL
  • Stock Information
  • Founded
  • SNTG 2009
  • ARTL 2011
  • Country
  • SNTG China
  • ARTL United States
  • Employees
  • SNTG N/A
  • ARTL 6
  • Industry
  • SNTG Finance: Consumer Services
  • ARTL Biotechnology: Pharmaceutical Preparations
  • Sector
  • SNTG Finance
  • ARTL Health Care
  • Exchange
  • SNTG Nasdaq
  • ARTL Nasdaq
  • Market Cap
  • SNTG 8.2M
  • ARTL 8.4M
  • IPO Year
  • SNTG 2021
  • ARTL N/A
  • Fundamental
  • Price
  • SNTG $2.70
  • ARTL $3.57
  • Analyst Decision
  • SNTG
  • ARTL Buy
  • Analyst Count
  • SNTG 0
  • ARTL 2
  • Target Price
  • SNTG N/A
  • ARTL $30.00
  • AVG Volume (30 Days)
  • SNTG 113.1K
  • ARTL 69.0K
  • Earning Date
  • SNTG 05-14-2025
  • ARTL 11-11-2025
  • Dividend Yield
  • SNTG N/A
  • ARTL N/A
  • EPS Growth
  • SNTG N/A
  • ARTL N/A
  • EPS
  • SNTG N/A
  • ARTL N/A
  • Revenue
  • SNTG $107,507.00
  • ARTL N/A
  • Revenue This Year
  • SNTG N/A
  • ARTL N/A
  • Revenue Next Year
  • SNTG N/A
  • ARTL N/A
  • P/E Ratio
  • SNTG N/A
  • ARTL N/A
  • Revenue Growth
  • SNTG N/A
  • ARTL N/A
  • 52 Week Low
  • SNTG $1.43
  • ARTL $3.91
  • 52 Week High
  • SNTG $12.70
  • ARTL $28.60
  • Technical
  • Relative Strength Index (RSI)
  • SNTG 44.56
  • ARTL 29.99
  • Support Level
  • SNTG $2.60
  • ARTL $3.94
  • Resistance Level
  • SNTG $3.20
  • ARTL $4.34
  • Average True Range (ATR)
  • SNTG 0.19
  • ARTL 0.37
  • MACD
  • SNTG -0.08
  • ARTL 0.04
  • Stochastic Oscillator
  • SNTG 13.94
  • ARTL 4.41

About SNTG Sentage Holdings Inc.

Sentage Holdings Inc is a financial service provider that offers a comprehensive range of financial services across consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China.

About ARTL Artelo Biosciences Inc.

Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.

Share on Social Networks: